Introduction Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition
needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is …

Background Delamanid is one of two recently approved drugs for the treatment of multidrug-
resistant tuberculosis. We aimed to evaluate the safety and efficacy of delamanid in the first …

Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with
worse treatment outcomes for patients, including higher mortality, than for drug-sensitive …

Background Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new
antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro …

Delamanid (Deltyba®), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB)
drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible …

Background Bedaquiline and delamanid are newly available drugs for treating multidrug-
resistant tuberculosis (MDR-TB); however, there are limited data guiding their use and no …

Experience with delamanid (Dlm) is limited, particularly among HIV-positive individuals. We
describe early efficacy and safety data from a programmatic setting in South Africa. This was …

Abstract Background Since 1 September 2016, bedaquiline and delamanid have been
administered for the treatment of patients with multidrug-resistant/rifampicin-resistant …

Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB),
has had limited use outside clinical trials. We present the early treatment results for 53 …

Background Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-
drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially …